Other studies have shown that the continuous activation of the AKT-related signalling pathway leads to enhanced chemoresistance in multiple cancer cells; for instance, activation of the AKT signalling pathway enhances platinum drug resistance in metastatic urothelial carcinoma and ovarian cancer [18–21] as well as in breast cancer [22]. This evidence concerns the gene AKT1 and ovarian carcinoma.